Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 5Neoplasms 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2GATA2 Deficiency 2Anemia, Refractory, with Excess of Blasts 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Hematologic Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5fludarabine 5Whole-Body Irradiation 4Busulfan 4Biopsy 4Specimen Handling 3Injections 3Cytarabine 3venetoclax 2decitabine and cedazuridine drug combination 2Tacrolimus 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporine 2CPX-351 2Azacitidine 2treosulfan 1peginterferon alfa-2b 1olutasidenib 1itacitinib 1canakinumab 1aldesleukin 1X-Rays 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × Azacitidine × 30 days × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03613532 2026-05-20

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
102 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡